Morgan Stanley set a €70.00 ($81.40) price objective on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research note issued to investors on Wednesday, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
Several other research firms also recently commented on FME. Nord/LB set a €92.00 ($106.98) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a buy rating in a research report on Friday, May 3rd. Goldman Sachs Group cut Micro Focus International from a neutral rating to a sell rating in a report on Tuesday, July 16th. Kepler Capital Markets set a €80.00 ($93.02) price target on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a report on Thursday, May 2nd. HSBC set a €101.00 ($117.44) price target on Grenke and gave the company a buy rating in a report on Thursday, April 25th. Finally, Jefferies Financial Group reaffirmed a buy rating and set a GBX 99 ($1.29) price target on shares of in a report on Friday, June 28th. Seven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of €82.57 ($96.01).
Fresenius Medical Care AG & Co. KGaA stock opened at €67.00 ($77.91) on Wednesday. The company has a debt-to-equity ratio of 100.05, a current ratio of 1.02 and a quick ratio of 0.67. The company has a market cap of $20.45 billion and a P/E ratio of 10.43. Fresenius Medical Care AG & Co. KGaA has a one year low of €55.44 ($64.47) and a one year high of €91.74 ($106.67). The stock’s 50 day moving average is €68.38.
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Recommended Story: What is intrinsic value?
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.